Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oral Atopic Dermatitis Market Crowded, But Arena Sees Room

Apr 23 2021

• By Alaric DeArment

Dermatitis — Arena plans a Phase III trial in the fourth quarter of 2021 • Source: Shutterstock

Related Content

Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Mar 19 2020

Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss

Nov 11 2020

Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

Nov 02 2020

AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

Jul 22 2020

Related Companies

Arena Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Novartis AG

Eli Lilly and Company

Incyte Corporation

Pfizer Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Business Strategies Clinical Trials Research & Development Dermatology BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.